sorafenib has been researched along with Colorectal Neoplasms in 56 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (14.29) | 29.6817 |
| 2010's | 38 (67.86) | 24.3611 |
| 2020's | 10 (17.86) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, T; Chen, T; Du, K; Gao, X; Luo, X; Shen, R; Sun, H; Wu, C; Wu, Y; Xi, M; Yu, L | 1 |
| Chen, X; Fan, T; Lowerison, M; Song, P; Zhang, W | 1 |
| Andersson, C; Blom, K; Brechot, C; Ek, F; Fryknäs, M; Jarvius, M; Larsson, R; Nygren, P; Rudfeldt, J; Selvin, T; Senkowski, W | 1 |
| Chi, HC; Huang, PS; Huang, YH; Liao, CJ; Lin, CC; Lin, KH; Lin, YH; Liou, YS; Liu, YC; Yeh, CT; Yu, CJ | 1 |
| Chen, L; Wang, J; Wang, L | 1 |
| Abaza, MS; Al-Attiyah, RJ; Bahman, A; Khoushaish, S | 1 |
| Chen, T; Chen, Y; Huang, T; Jiang, Y; Li, N; Sun, H; Wu, M; Yan, X; Yang, Q | 1 |
| Babos, G; Feczkó, T; Fodor-Kardos, A; Kawalec, M; Klim, M; Rydz, J; Trif, L | 1 |
| Jeong, KY; Kim, HM; Park, M; Sim, JJ | 1 |
| Ali, A; Daily, KC; Dang, LH; George, TJ; Iqbal, A; Ivey, AM; Lee, JH; Ramnaraign, BH; Read, TE; Tan, SA; Terracina, KP; Wang, Y | 1 |
| Basto, R; Conde, RS; Dal Lago, L; Deleporte, A; Hendlisz, A; Monteiro, AR; Sclafani, F | 1 |
| Lou, L; Quan, H; Wang, H | 1 |
| Karasic, TB; O'Dwyer, PJ; Rosen, MA | 1 |
| Alonso, V; Asensio, E; Camps, J; Castells, A; Codony-Servat, J; Cuatrecasas, M; Escudero, P; Feliu, J; Fernández-Martos, C; Gaba, L; Gallego, J; García-Albéniz, X; Horndler, C; Jares, P; Marín-Aguilera, M; Martín-Richard, M; Martínez-Balibrea, E; Martínez-Cardús, A; Maurel, J; Méndez, JC; Méndez, M; Montironi, C; Prat, A; Reig, O; Rojo, F; Rosell, R; Rubini, M; Salud, A; Victoria, I | 1 |
| Heller, D; Kimura, Y; Kodama, H; Shah, J; Shamay, Y; Solomon, SB; Srimathveeravalli, G | 1 |
| Cai, H; Chen, Y; Jiang, G; Li, N; Long, F; Wang, Q; Wang, T; Wu, M; Xiao, H; Xu, B; Yan, X; Zhong, L | 1 |
| Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L | 1 |
| Al-Marrawi, MY; Brennan, MC; Dykes, TM; El-Deiry, WS; Saroya, BS; Yang, Z | 1 |
| Assenat, E; Causse, A; Del Rio, M; Evrard, A; Gongora, C; Jarlier, M; Leconet, W; Martineau, P; Mazard, T; Robert, B; Simony, J; Torro, A; Vezzio-Vie, N; Ychou, M | 1 |
| Adenis, A; Assenat, E; Bennouna, J; Bibeau, F; Boissière, F; Bouché, O; Conroy, T; Crapez, E; Desseigne, F; Francois, E; Galais, MP; Laurent-Puig, P; Mazard, T; Poujol, S; Samalin, E; Seitz, JF; Taieb, J; Thézenas, S; Ychou, M | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Fujiya, T; Hasegawa, Y; Kakugawa, Y; Kinouchi, M; Miura, K; Philchenkov, A; Satoh, M; Yamamoto, K | 1 |
| Jung, WG; Kim, EH; Kim, MS | 1 |
| Cao, L; Choyke, P; Do, K; Doroshow, JH; Eugeni, M; Figg, WD; Holkova, B; Jacobs, P; Kang, Z; Kummar, S; Larkins, E; Lindenberg, ML; Peer, CJ; Raffeld, M; Steinberg, SM; Turkbey, B; Wright, JJ | 1 |
| Chen, YC; Chin, SY; Chou, CL; Jiang, MC; Lee, WR; Liu, KH; Shen, SC; Shih, YH; Tseng, JT | 1 |
| Ameye, L; Barbuto, AM; Ceyssens, S; Delaunoit, T; Deleporte, A; Demolin, G; El Mansy, H; Filleul, B; Flamen, P; Garcia, C; Guiot, T; Hendlisz, A; Holbrechts, S; Houbiers, G; Lhommel, R; Maréchal, R; Moreau, M; Paesmans, M; Peeters, M; Piccart, M; Van den Eynde, M; Van Laethem, JL | 1 |
| Abdel-Rahman, O | 1 |
| Ameye, L; Delaunoit, T; Deleporte, A; Demolin, G; Flamen, P; Garcia, C; Gauthier, N; Guiot, T; Hendlisz, A; Holbrechts, S; Lhommel, R; Maréchal, R; Van den Eynde, M; Vierasu, I; Woff, E | 1 |
| Becker, M; Galle, PR; Martchenko, K; Möhler, M; Schimanski, CC; Schmidtmann, I; Thole, V; Thomaidis, T; Wehler, TC | 1 |
| Tan, S; Tong, J; Yu, J; Zhang, L; Zou, F | 1 |
| Chen, KF; Fan, LC; Hung, MH; Jiang, JK; Shiau, CW; Tai, WT; Teng, HW; Yang, SH | 1 |
| Bauernhofer, T; Gerger, A; Hutterer, GC; Karbiener, M; Kiesslich, T; Mayr, C; Pehserl, AM; Pichler, M; Resel, M; Ress, AL; Scheideler, M; Stadelmeyer, E; Stanzer, S; Stiegelbauer, V | 1 |
| Hu, Y; Lin, A; Ma, C; Niu, Y; Shi, L; Su, Y; Zhang, C; Zhou, L; Zhu, X | 1 |
| Arena, S; Bardelli, A; De Dosso, S; Di Nicolantonio, F; Frattini, M; Martini, M; Mazzucchelli, L; Molinari, F; Saletti, P; Sartore-Bianchi, A; Siena, S | 1 |
| Azizi, M; Bobrie, G; Bouché, O; Deray, G; des Guetz, G; Halimi, JM; Lecomte, T; Levy, B; Mourad, JJ; Nochy, D; Oudard, S; Rieu, P; Sahali, D | 1 |
| Altorki, NK; Alvarez, H; Beer, DG; Boonstra, JJ; Chaves, P; Darnton, SJ; Dinjens, WN; Eshleman, JR; Klimstra, DS; Lin, L; Pereira, AD; Ribeiro, C; Roque, L; Schrump, DS; Shimada, Y; Tang, LH; Tilanus, HW; van Dekken, H; van Marion, R | 1 |
| Grothey, A; Hubbard, J | 1 |
| Burger, AM; Egorin, MJ; Heilbrun, LK; Horiba, MN; Ivy, P; Li, J; Lorusso, PM; Pacey, S; Sausville, EA; Vaishampayan, UN | 1 |
| Downing, L; Galoforo, S; Marples, B; Martinez, AA; McGonagle, M; Robertson, JM; Suen, AW; Wilson, GD | 1 |
| Berrino, L; Capasso, A; Ciardiello, F; De Vita, F; Eckhardt, SG; Martinelli, E; Morelli, MP; Morgillo, F; Orditura, M; Rodolico, G; Santoro, M; Troiani, T; Tuccillo, C; Vecchione, L; Vitagliano, D | 1 |
| Curtit, E; Le Tourneau, C; Mansi, L; Medioni, J; Viel, E | 1 |
| Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Navaraj, A; Smith, CD; Wang, W | 1 |
| Chang, YF; Chen, CL; Chen, CW; Chiang, IT; Hwang, JJ; Kuo, YC; Lin, WC; Su, SH | 1 |
| Arcaroli, J; Azad, N; Carducci, MA; Dasari, A; Diaz, LA; Donehower, RC; Hidalgo, M; Laheru, DA; McManus, M; Messersmith, WA; Quackenbush, K; Rudek, MA; Taylor, GE; Wright, JJ; Zhao, M | 1 |
| Dong, J; Evers, BM; Gao, T; Gulhati, P; Kim, JT; Lee, EY; Sasazuki, T; Shirasawa, S; Stevens, PD; Valentino, JD; Weiss, HL; Zaytseva, YY | 1 |
| Fan, X; Haney, CR; Karczmar, GS; Markiewicz, E; Mustafi, D; Stadler, WM | 1 |
| Chung, HC; Jeong, I; Jeung, HC; Kim, GE; Kim, YB; Lee, K; Rha, SY | 1 |
| Berger, MR; Galle, PR; Gockel, I; Graf, C; Hainz, M; Hamdi, S; Maderer, A; Moehler, M; Schimanski, CC; Schmidtmann, I; Theobald, M; Wehler, TC | 1 |
| Del Rio, A; Grossi, V; Ingravallo, G; Liuzzi, M; Martelli, N; Murzilli, S; Napoli, A; Simone, C | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Brendel, E; Christensen, O; Henning, BF; Hilger, RA; Hofstra, E; Kupsch, P; Passarge, K; Richly, H; Scheulen, ME; Schwartz, B; Seeber, S; Strumberg, D; Voigtmann, R; Wiesemann, K | 1 |
| Soff, G; Zakarija, A | 1 |
| Cerniglia, G; Dicker, DT; Diehl, JA; Dorsey, JF; El-Deiry, WS; Flaherty, KT; Gupta, A; Kim, SH; Liu, YY; McDonough, J; Plastaras, JP; Rajendran, RR; Rustgi, AK; Smith, CD | 1 |
| Alba, E; Medina, MA; Quesada, AR | 1 |
12 review(s) available for sorafenib and Colorectal Neoplasms
| Article | Year |
|---|---|
CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors.
Topics: Colorectal Neoplasms; Cyclin-Dependent Kinase 8; Drug Discovery; Humans; Mediator Complex; Molecular Structure; Neoplasms; Oncogenes; Protein Kinase Inhibitors; Wnt Signaling Pathway | 2019 |
Targeted agents in older patients with gastrointestinal cancers - An overview.
Topics: Aged; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; Gastrointestinal Neoplasms; Humans; Panitumumab; Sorafenib | 2021 |
Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Colorectal Neoplasms; Humans; Models, Biological; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Rate | 2017 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
The preclinical development of regorafenib for the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Colorectal Neoplasms; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2014 |
Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Sorafenib | 2016 |
Antiangiogenesis agents in colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
[Targeting the RAS signalling pathway in cancer].
Topics: Antineoplastic Agents; Benzenesulfonates; Colorectal Neoplasms; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; ras Proteins; Signal Transduction; Sorafenib | 2011 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors.
Topics: Benzenesulfonates; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2003 |
Update on angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2005 |
Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
9 trial(s) available for sorafenib and Colorectal Neoplasms
| Article | Year |
|---|---|
Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Sorafenib; Treatment Outcome | 2021 |
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neutropenia; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib | 2014 |
A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Sorafenib; Vascular Endothelial Growth Factor A; Young Adult | 2015 |
The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Female; Glucose-6-Phosphate; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Prospective Studies; Radiography; Sorafenib; Survival Rate | 2015 |
Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Drug Monitoring; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2016 |
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzoquinones; Clinical Trials, Phase II as Topic; Cohort Studies; Colorectal Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Lactams, Macrocyclic; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis | 2010 |
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Tissue Distribution | 2013 |
Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Colorectal Neoplasms; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Sorafenib | 2005 |
35 other study(ies) available for sorafenib and Colorectal Neoplasms
| Article | Year |
|---|---|
Characterization of Anti-Angiogenic Chemo-Sensitization via Longitudinal Ultrasound Localization Microscopy in Colorectal Carcinoma Tumor Xenografts.
Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Colorectal Neoplasms; Heterografts; Humans; Microscopy; Sorafenib; Xenograft Model Antitumor Assays | 2022 |
Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Colorectal Neoplasms; Humans; Liver Neoplasms; Mitochondria; Nitro Compounds; Sorafenib; Thiazoles | 2022 |
CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromatin; Colorectal Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Mice, Nude; RNA, Long Noncoding; Sorafenib; YY1 Transcription Factor | 2022 |
TIMP1 represses sorafenib-triggered ferroptosis in colorectal cancer cells by activating the PI3K/Akt signaling pathway.
Topics: Colorectal Neoplasms; Ferroptosis; Humans; Iron; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Sorafenib; Tissue Inhibitor of Metalloproteinase-1 | 2023 |
Therapeutic efficacy of sorafenib and plant-derived phytochemicals in human colorectal cancer cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Humans; Sorafenib; United States | 2023 |
Decreasing acute toxicity and suppressing colorectal carcinoma using Sorafenib-loaded nanoparticles.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Carriers; Drug Compounding; Endocytosis; Human Umbilical Vein Endothelial Cells; Humans; Lethal Dose 50; Mice; Mice, Inbred BALB C; Nanoparticles; Particle Size; Polyesters; Polyethylene Glycols; Sorafenib; Toxicity Tests, Acute | 2020 |
Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery.
Topics: Colorectal Neoplasms; Doxorubicin; Drug Carriers; Drug Delivery Systems; HCT116 Cells; Humans; Nanoparticles; Polyethylene Glycols; Polylactic Acid-Polyglycolic Acid Copolymer; Prohibitins; Sorafenib | 2020 |
Combination Antitumor Effect of Sorafenib via Calcium-Dependent Deactivation of Focal Adhesion Kinase Targeting Colorectal Cancer Cells.
Topics: Antineoplastic Agents; Calcium; Cell Cycle; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Focal Adhesion Kinase 1; HCT116 Cells; HT29 Cells; Humans; Lactic Acid; Signal Transduction; Sorafenib | 2020 |
AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Topics: Antineoplastic Agents; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Imidazoles; Mutation; Niacinamide; Oximes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Sorafenib; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Nucleus; Cell Survival; Cetuximab; Colorectal Neoplasms; Curcumin; Dasatinib; Drug Resistance, Neoplasm; Fatty Acids, Unsaturated; Female; Fluorouracil; Gene Silencing; HCT116 Cells; HT29 Cells; Humans; Leucovorin; Male; Middle Aged; Molecular Chaperones; Molecular Targeted Therapy; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Protein Inhibitors of Activated STAT; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib | 2017 |
Electroporation-induced changes in tumor vasculature and microenvironment can promote the delivery and increase the efficacy of sorafenib nanoparticles.
Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Drug Delivery Systems; Electroporation; Female; HCT116 Cells; Humans; Mice; Mice, Nude; Nanoparticles; Sorafenib; Tumor Microenvironment | 2019 |
Polymer-based nanoparticles for chemo/gene-therapy: Evaluation its therapeutic efficacy and toxicity against colorectal carcinoma.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Eye Proteins; Genetic Therapy; HEK293 Cells; Humans; Inhibitory Concentration 50; Mice, Inbred BALB C; Nanoparticles; Nerve Growth Factors; Polymers; Serpins; Sorafenib; Toxicity Tests, Acute; Treatment Outcome | 2019 |
Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Female; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Off-Label Use; Panitumumab; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib | 2013 |
Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Mice; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
The mechanisms responsible for the radiosensitizing effects of sorafenib on colon cancer cells.
Topics: Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; DNA Damage; Humans; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Radiation Tolerance; Radiation-Sensitizing Agents; Sorafenib | 2014 |
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Lapatinib; Male; Melanoma; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Quinazolines; Sorafenib; Sulfonamides; Sunitinib; Vemurafenib; Xenograft Model Antitumor Assays | 2015 |
Last line therapy with sorafenib in colorectal cancer: A retrospective analysis.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Neoplasm Staging; Niacinamide; Off-Label Use; Phenylurea Compounds; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Sorafenib; Withholding Treatment | 2016 |
FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.
Topics: Animals; Cell Cycle Proteins; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Female; Gene Knockout Techniques; HCT116 Cells; Heterografts; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation, Missense; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Transfection; Ubiquitin-Protein Ligases | 2017 |
Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Cadherins; Cell Movement; Colorectal Neoplasms; Dose-Response Relationship, Drug; Enzyme Activation; Epithelial-Mesenchymal Transition; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Male; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyridines; RNA Interference; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Time Factors; Transfection; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2016 |
Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
Topics: Animals; Caco-2 Cells; Cell Cycle Checkpoints; Colorectal Neoplasms; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Sorafenib | 2016 |
Matrix Metalloproteinase Responsive Nanoparticles for Synergistic Treatment of Colorectal Cancer via Simultaneous Anti-Angiogenesis and Chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Liberation; HT29 Cells; Humans; Male; Matrix Metalloproteinase 2; Mice, Inbred BALB C; Nanoparticles; Niacinamide; Phenylurea Compounds; Photoacoustic Techniques; Rats, Sprague-Dawley; Sorafenib; Tissue Distribution; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Survival; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Italy; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Panitumumab; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Retrospective Studies; Sorafenib; Switzerland; Time Factors; Treatment Outcome | 2008 |
[Vascular and renal effects of anti-angiogenic therapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Glomerular Filtration Rate; Glomerulonephritis; Humans; Indoles; Kidney; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Biomedical Research; Carcinoma; Carcinoma, Large Cell; Cell Line, Tumor; Clinical Trials as Topic; Colorectal Neoplasms; DNA Fingerprinting; Esophageal Neoplasms; Humans; Lung Neoplasms; National Institutes of Health (U.S.); Niacinamide; Oligonucleotides; Oligopeptides; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Stomach Neoplasms; Tandem Repeat Sequences; Telomerase; United States | 2010 |
Sorafenib and radiation: a promising combination in colorectal cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzenesulfonates; Cell Division; Colorectal Neoplasms; Combined Modality Therapy; HT29 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiation Tolerance; Radiotherapy Dosage; Random Allocation; Sorafenib; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2010 |
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cetuximab; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2010 |
Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Synergism; Female; Fluorouracil; Humans; Mice; Mice, Nude; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins p21(ras); Pyridines; Quinacrine; ras Proteins; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2011 |
Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, SCID; NF-kappa B; Niacinamide; Phenylurea Compounds; Pyridines; Radiation-Sensitizing Agents; Sorafenib; Xenograft Model Antitumor Assays | 2012 |
Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Synergism; Humans; Male; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Mutation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases | 2012 |
Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis.
Topics: Angiogenesis Inhibitors; Animals; Colorectal Neoplasms; Contrast Media; Disease Models, Animal; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Transplantation, Heterologous | 2013 |
Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Cell Survival; Chemoradiotherapy; Colorectal Neoplasms; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; HT29 Cells; Humans; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Radiation Dosage; Radiation Tolerance; Sorafenib; Treatment Outcome | 2013 |
Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Intercellular Signaling Peptides and Proteins; Ki-67 Antigen; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Sorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response.
Topics: Animals; Apoptosis; Caspase 3; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; Female; Humans; Imidazoles; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 14; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Transplantation, Heterologous | 2012 |
ASCO 2007: plenary top 5.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Humans; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Lung Neoplasms; Medical Oncology; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Societies, Medical; Sorafenib; United States | 2007 |
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Division; Cell Growth Processes; Colorectal Neoplasms; Combined Modality Therapy; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Radiation; Drug Administration Schedule; Endothelial Cells; Female; G2 Phase; HCT116 Cells; Humans; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Retinoblastoma Protein; Sorafenib; Xenograft Model Antitumor Assays | 2007 |